Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Launches A WeC3G Initiative To Raise Awareness For C3G


Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has owned up the commitment to raising public awareness of the C3 glomerulopathy (“C3G”). The biopharmaceutical company says that it will be launching a new patient support initiative called WeC3G, with an aim to bring together those living with C3G.  This is an exceptional but chronic disease affecting the kidneys and according to the experts, it affects the alternative pathway of the immune system.

Records have it that close to 4,000 people in the United States living with C3G and apparently, there are no approved treatments. However, the launch by Achillion will contain supportive resources and educational materials for the patient and the caregiver.  It will also provide an opportunity to sign up for ongoing news and updates.

Achillion is steadfastly committed to innovative research

The biopharma founded in February 2000 as one of the biggest startups have been growing from strength to strength since its inception. Having assembled the necessary scientific and technological resources, its primary role is to address the unmet medical needs of patients with C3G. The goal will be achieved through advancing the development innovative products and potentially disease-modifying therapies.

The move by Achillion is remarkable according to the company’s Chief Executive Officer, Milind Deshpande. The officer comments, “Achillion is proud of its sponsorship of WeC3G, along with other recent efforts, such as supporting a global natural history study of C3G to track the course of this disease.”

The success of biotechnology companies has made them increasingly valuable

As the world revolves around technology, biotech companies have not been spared either in staying up to the trends. Achillion is a product-focused pharmaceutical company playing significant roles in the discovery and commercial development of innovative therapeutic agents. It has leveraged its internal its capabilities in drug development platform. The company is also focusing on modulation of the complement system via oral small-molecules.

Apparently, not many are aware that the rare disease causes chronic deposition of C3 fragments, which can result in permanent renal damage.  It is a devastating illness and affects men and women equally. It is so serious such that estimates show that within 10years, 30-50% of C3G patients will require dialysis or a transplant.


Please enter your comment!
Please enter your name here